Ekadharma International Tbk PT

Ekadharma International Tbk PT maintains a strong liquidity position, with a current ratio of 13.88, indicating a significant buffer of current assets relative to current liabilities. The company's cash and equivalents amount to 101,933,403,180 IDR, which is a substantial portion of its total assets. The price-to-book ratio of 0.53 suggests that the company is trading at a discount to its book value, potentially indicating undervaluation or asset-heavy operations.

In terms of profitability, Ekadharma's return on equity (ROE) is 2.16%, and its return on assets (ROA) is 1.92%. These figures are below the typical thresholds for high-performing specialty chemical firms, suggesting that the company may not be generating returns as efficiently as its peers. The company's gross profit margin is 32.07%, and its operating margin is 21.74%, which are in line with industry norms but do not indicate exceptional performance.

The company's revenue is concentrated in a single business segment, as disclosed in its financial reports, with no material geographic diversification reported. This lack of diversification could expose the company to regional economic fluctuations and regulatory changes. The company's revenue for the latest period is 123,884,573,220 IDR, and while there is no specific growth trajectory provided, the company's operating cash flow of 29,934,007,920 IDR suggests a stable cash-generating business.

Ekadharma's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.02, which is very low and suggests a conservative capital structure with minimal leverage. The company has not issued any new shares recently, and there are no indications of near-term dilution pressure.

Recent financial filings and transcripts do not highlight any significant events or strategic shifts. The company's latest actual revenue of 643,591,820,000 IDR is lower than the reported revenue of 123,884,573,220 IDR, which may indicate a discrepancy in reporting periods or a need for further clarification. The company's capital expenditure of -5,929,932,100 IDR suggests a reduction in capital spending, which could be a strategic move to preserve cash or a sign of reduced investment in growth initiatives.

Debt-to-equity ratio of 0.02 is above the 75th percentile, reflecting a highly conservative capital structure.

Cash conversion of 1.24 exceeds the 1.08 cohort median, suggesting robust cash generation relative to earnings.

Low dilution, liquidity, and credit risk flags indicate a stable operational environment with minimal immediate threats.

Return on equity of 2.16% lags the 3.93% cohort median, indicating inefficient use of shareholder capital.

Revenue growth stagnated with a 0.0% four-year CAGR, showing an inability to expand the top line.

Revenue IDR 142.34B, +10,7% YoY.

• ▍Revenue IDR 142.34B, +10,7% YoY

Revenue IDR 529.53B, −0,2% YoY; Operating income −28,5% YoY.

• ▍Revenue IDR 529.53B, −0,2% YoY
• ▍Operating income −28,5% YoY
• ▍Net income −17,7% YoY
• ▍Free cash flow −31,9% YoY
• ▍Net margin 10.0%